<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63713">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01841437</url>
  </required_header>
  <id_info>
    <org_study_id>GTS100-PAR</org_study_id>
    <nct_id>NCT01841437</nct_id>
  </id_info>
  <brief_title>Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry</brief_title>
  <official_title>Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glaukos Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe the safety of the Glaukos® iStent® Trabecular
      Micro-Bypass Stent Model GTS100 in conjunction with cataract surgery in subjects with mild
      to moderate open-angle glaucoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>Rate of sight-threatening adverse events</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other ocular adverse events</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Primary Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>iStent</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iStent</intervention_name>
    <arm_group_label>iStent</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive subjects in whom implantation of the iStent is attempted at selected clinical
        sites
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive subjects in whom implantation of the iStent is attempted

        Exclusion Criteria:

          -  Please refer to approved indications in Directions for Use
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Silke Thode, PhD</last_name>
    <phone>949-367-9600</phone>
    <email>sthode@glaukos.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeff Wells, PharmD, MBA</last_name>
    <phone>949-367-9600</phone>
    <email>jwells@glaukos.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Chico</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Brecksville</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Ladson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Thode</last_name>
      <phone>949-367-9600</phone>
      <email>sthode@glaukos.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>December 16, 2013</lastchanged_date>
  <firstreceived_date>April 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary open-angle glaucoma (POAG)</keyword>
  <keyword>Trabecular meshwork</keyword>
  <keyword>iStent</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
